Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression

The goal of this clinical trial is to learn if adding the TheraBionic P1 device to standard of care third line treatment for adult women with metastatic triple negative breast cancer (mTNBC) who have failed, not tolerated, or progressed on standard first- and second-line treatment options can work better than the standard of care alone. The main questions it aims to answer is: * will the addition of the TheraBionic P1 device to standard of care third line treatment affect progression free and overall survival in these participants

NCT Number	NCT07672431
Lead Sponsor	Barbara Ann Karmanos Cancer Institute Collaborators: THERABIONIC INC., Ucancervive
Conditions	Triple Negative Breast Cancer
Enrollment	24 participants
Start Date	2026-09
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-29